which can be explained by the lack of effective early diagnosis, treatment delay, and high prevalence of nosocomial infection in the ICU. 3, 4 Effective treatments in sepsis rely on timely removal of the source of infection and appropriate choice of antimicrobial therapy, whereas there are still a large number of sepsis patients die from delayed diagnosis and ineffective treatment. Therefore, the exploration of potential biomarkers, which can promote sensitivity and specificity of diagnosis and prognosis, is essential to achieve optimized treatment outcomes and increased survival in sepsis patients. 5, 6 JNK pathway-associated phosphatase (JKAP), also known as dual-specificity phosphatase (DUSP) 22, serves as a tyrosine phosphatase and specifically activates kinases JNK. 7 It is expressed in various types of human cells such as T cells, B cells, and natural killer cells, suggesting that JKAP is possibly involved in immune and inflammation response of human diseases. 8, 9 Moreover, evidence reveals that JKAP is downregulated and negatively correlates with inflammation level and disease activity in systemic lupus erythematosus (SLE) as well as inflammatory bowel disease (IBD). 8, 9 Considering the above-mentioned data which indicate that JKAP is a key factor in regulating immune, inflammation and is closely involved in the etiology of several inflammatory diseases, we hypothesize it might participate in the development and progression of sepsis.
However, no related research has been reported until now. Thus, we performed this study to explore the association of JKAP expression with sepsis risk and investigate its correlation with disease severity, inflammatory cytokines, and survival in sepsis patients.
| MATERIAL S AND ME THODS

| Participants
This study consecutively recruited 101 sepsis patients who were ad- 
| Data collection
After the enrollment, all patients' data were collected, which consisted of the following: (a) demographic data: age, gender, BMI, and smoke; (b) chronic comorbidities: chronic obstructive pulmonary disease (COPD), cardiomyopathy, chronic kidney failure, and cirrhosis; (c) laboratory indexes: serum creatinine (Scr), albumin, white blood cell (WBC), C-reactive protein (CRP), and procalcitonin (PCT).
| Assessments and follow-up
Acute physiology and chronic health evaluation (APACHE) II score and sequential organ failure assessment (SOFA) score were assessed within 24 hours after admission to the Department of Emergency Medicine. For the APACHE II score, the evaluation was composed of three parts, including physiologic scores ranging from 0 to 60 points, age scores ranging from 0 to 6 points, and comorbid disease scores ranging from 0 to 5 points, with a distribution of 0 to 71 points. The severity was increased when the APACHE II score was higher. 11 The SOFA scoring scheme assigned 1 to 4 points to each level of dysfunction of six organs (respiratory, circulatory, renal, hematological, hepatic, and central nervous systems). A score of 0 to 24 points was assigned, and a higher score was associated with an increased severity. 12 After enrollment, all patients were monitored daily and consecutively followed up for 28 days, and the 28-day mortality was recorded. Accumulating survival was calculated from the day of admission to the day of death in the hospital or last visit.
| Samples collection
Blood samples of sepsis patients were collected within 24 hours after admission, and those of healthy controls were collected on the enrollment. For separation of serum, the centrifugation was performed at the condition of 3000 r/min，15 minutes，4°C, within 1 hour after the blood samples collection. After the centrifugation, the serums were stored at −80°C until determination.
| Detection of JKAP and inflammatory cytokines in serum
The JKAP levels in serum of sepsis patients and healthy controls were determined by enzyme-linked immunoassay (ELISA) with human ELISA Kits designed by Shanghai Enzyme-linked Biotechnology Co., Ltd.
(Enzyme-linked Biotechnology). The inflammatory cytokines expressions including tumor necrosis factor (TNF-α), interleukin-1β (lL-1β), IL-6, and IL-17 in the serum of sepsis patients were determined by ELISA with commercial human ELISA Kits (eBioscience). All the procedures of ELISA were performed in accordance with the manufacturer's instructions.
| Statistical analysis
Data of this study were presented as mean (standard deviation 
| Comparison of JKAP level between sepsis patients and healthy controls
The median of JKAP level in sepsis patients (N = 101) was 12.890 (6.485-20.265) pg/mL, which was decreased compared with the healthy controls (N = 100) (54.228 [29.339-82.223] pg/mL) (P < 0.001; Figure 1A ). And ROC curve analysis exhibited that JKAP level was of great value in distinguishing sepsis patients from healthy controls with AUC of 0.896 (95% CI: 0.851-0.941; Figure 1B) . The sensitivity and specificity at the best cutoff point (the point where the sum of sensitivity and specificity was the largest) were 94.1% and 77.0%, respectively, and the cutoff value of JKAP was 28.083 pg/ mL. These data indicated JKAP presented with potential to be a biomarker for decreased sepsis risk.
| Correlation of JKAP level with disease severity, laboratory indexes, and inflammatory cytokines
In sepsis patients, JKAP level was negatively associated with both APACHE II score (r = −0.356, P < 0.001) and SOFA score (r = −0.343, P < 0.001; Table 2 
| Comparison of JKAP level between deaths and survivors
Among the 101 sepsis patients, the 28-day mortality was 32.7% and the survival rate was 67.3% (Figure 2A Figure 2B ).
In addition, the ROC curve displayed that JKAP level was of good value in distinguishing the deaths from the survivors in sepsis patients with AUC of 0.742 (95% CI: 0.636-0.849) with a sensitivity of 42.4% and a specificity of 97.1% at the best cutoff point, and the cutoff value of JKAP was 5.375 pg/mL ( Figure 2C ). These data indicated JKAP exhibited the potential to be a biomarker for decreased mortality. 
| Factors affecting 28-day mortality by logistic regression model analyses
Univariate logistic regression revealed that JKAP level was negatively correlated with 28-day mortality (OR = 0.232, P = 0.002), while APACHE II score (OR = 2.533, P = 0.036), SOFA score (OR = 7.407, P < 0.001), Scr (OR = 2.657, P = 0.026), WBC (OR = 2.353, P = 0.050), CRP (OR = 3.286, P = 0.008), PCT (OR = 2.857, P = 0.018), TNF-α (OR = 3.810, P = 0.004), IL-1β (OR = 6.810, P < 0.001), and IL-17
(OR = 2.500, P = 0.036) were positively associated with 28-day (Table 3 ). Furthermore, multivariate logistic regression further displayed that JKAP was not an independent predicting factor for 28-day mortality in sepsis patients (OR = 0.324, P = 0.129), while SOFA score (OR = 5.252, P = 0.028) and IL-1β (OR = 9.919, P = 0.023) were independent predictors of increased 28-day mortality in sepsis patients. These data suggested that the JKAP level might contribute to decreased 28-day mortality by influencing some clinical features such as inflammatory cytokines and disease severity.
| Correlation of JKAP expression with accumulating survival
Kaplan-Meier curve was further drawn for assessing the accumulating survival in sepsis patients, which disclosed that the mean value of accumulating survival in total sepsis patients was 22 (95% CI: 20.2-23.7) days ( Figure 3A) Figure 3B ). These data implied that JKAP high expression predicted better accumulating survival in sepsis patients. 
| Factors affecting accumulating survival by Cox's proportional hazards regression model analyses
| D ISCUSS I ON
In the present study, we observed that (a) JKAP level was negatively correlated with sepsis risk, and decreased JKAP level was associated with higher disease severity and inflammation in sepsis patients. (b) JKAP had good value in distinguishing deaths from survivors, and its high expression was associated with decreased 28-day mortality and more prolonged accumulating survival, while SOFA score and IL-1β
independently predicted increased 28-day mortality and worse accumulating survival in sepsis patients.
Sepsis is a complex disease united by the stimulation of systemic inflammation and the host response to infection. 13 Timely recognition is the crucial issue of sepsis, which is based on non-specific physiological criteria and identification of the infection, whose failure often causes the delay in the diagnosis and generating treatment, leading to unfavorable outcomes in sepsis patients. 5 Additionally, the sepsis patients who are admitted in ICU often face unacceptably high shortterm mortality and undesirable prognosis in the long term due to advanced disease severity and accompanying disease complications, which leads to a considerable consumption of healthcare resources and substantial burden for society. 14 Thus, it is essential to explore potential new biomarkers as adjuvants for recognizing sepsis risk and identifying the sepsis patients at high risk of having a poor prognosis.
JKAP is a member of DUSPs family, which is a group of cysteine-based protein tyrosine phosphatases, and is involved in the pathogenesis of several human diseases. 15 There has been evidence in the last decade that JKAP regulates autoimmunity in various diseases through inactivating T-cell receptor signaling and further suppressing T-cell immune responses. 6, 15 For example, a study reveals that JKAP in peripheral blood T cells is downregulated in SLE patients compared to health controls; besides, its downregulation is correlated with increased SLE disease activity index in SLE patients and is associated with higher daily urinary protein amounts and poorer renal outcomes in SLE-nephritis patients. 9 In another study, JKAP in mucosa is decreased in active IBD patients compared to IBD patients at remission and health controls and is negatively correlated with disease activity as well as systemic inflammation in IBD patients; also, JKAP is observed to suppress CD4 + T-cell activation and Th1/Th17 Cell differentiation in IBD. 8 Given that SLE and IBD both belong to immune and inflammatory diseases, we speculated that the expression of JKAP might also be dysregulated and play a critical role in sepsis.
We found that JKAP had the potential for predicting decreased sepsis risk and downregulation of JKAP was associated with exac- Currently, there is limited study focusing on the association of JKAP and prognosis in diseases related to immunity and inflammation. Only one paper indicates that high expression of JKAP predicts a better response to anti-TNF-α treatment in IBD patients. 8 In our study, we found that JKAP expression was associated with disease risk and severity of sepsis; thus, we speculated that JKAP might be of prognostic importance in sepsis patients. Therefore, we conducted further assessments and discovered that JKAP level was negatively correlated with survival, while it was not able to independently predict poor survival in sepsis patients. These could be explained by the following: (a) Downregulation of JKAP might promote T cell-me- severity, to influence the survival; hence, JKAP was not an independent predictive factor for survival in sepsis patients. 6 This might be supported by one of our findings which elucidated that JKAP was negatively correlated with APACHE II score, SOFA score, TNF-α, IL-1β, IL-6, and IL-17, and that SOFA score and IL-1β were independent predictive factors for decreased survival in sepsis patients.
SOFA score reflects the facets of organ dysfunction; therefore, the sepsis patients with high SOFA score might have more severe organ dysfunction, which contributed to the undesirable survival. 16, 17 Additionally, IL-1β was a well-known proinflammatory cytokine; therefore, the high expression of IL-1β might lead to the activation of the inflammasome response, as well as predict the worse survival in sepsis patients. 18 There were several limitations to our studies. In summary, JKAP is of good value in predicting lower sepsis risk and its downregulation correlates with advanced disease severity, higher level of systemic inflammation, and poor survival in sepsis patients.
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